Safe Delivery 99% Purity CAS 941678-49-5 Ruxolitinib Raw Powder Ruxolitinib Phosphate

Product Details
Customization: Available
Powder: Yes
Customized: Customized
Diamond Member Since 2021

Suppliers with verified business licenses

Audited Supplier Audited Supplier

Audited by an independent third-party inspection agency

Number of Employees
14
Year of Establishment
2017-02-08
  • Safe Delivery 99% Purity CAS 941678-49-5 Ruxolitinib Raw Powder Ruxolitinib Phosphate
  • Safe Delivery 99% Purity CAS 941678-49-5 Ruxolitinib Raw Powder Ruxolitinib Phosphate
  • Safe Delivery 99% Purity CAS 941678-49-5 Ruxolitinib Raw Powder Ruxolitinib Phosphate
  • Safe Delivery 99% Purity CAS 941678-49-5 Ruxolitinib Raw Powder Ruxolitinib Phosphate
  • Safe Delivery 99% Purity CAS 941678-49-5 Ruxolitinib Raw Powder Ruxolitinib Phosphate
  • Safe Delivery 99% Purity CAS 941678-49-5 Ruxolitinib Raw Powder Ruxolitinib Phosphate
Find Similar Products

Basic Info.

Model NO.
ruxolitinib
Certification
GMP, HSE, ISO 9001, USP, BP
Suitable for
Adult
State
Solid
Purity
>99%
Name
Ruxolitinib
Mf
C17h21n6o4p
CAS
1092939-17-7
MOQ
10g
Transport Package
Drum
Specification
99%
Trademark
HNB
Origin
China
HS Code
29323324
Production Capacity
500000

Product Description

Safe delivery 99% Purity CAS 941678-49-5 Ruxolitinib Raw Powder
Product name Ruxolitinib Ruxolitinibe Em Po Polvo
CAS 941678-49-5
Molecular formula C17H18N6
Molecular weight 306.37
EINECS number 1312995-182-4
Purity >99%
Standard Pharmaceutical Grade
 
Ruxolitinib is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera (PCV) when there has been an inadequate response to or intolerance of hydroxyurea.
Safe Delivery 99% Purity CAS 941678-49-5 Ruxolitinib Raw Powder Ruxolitinib Phosphate

What is Ruxolitinib phosphate?

The phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.

Ruxolitinib phosphate is approved to treat:
1) Myelofibrosis (a bone marrow disease) that is intermediate or high-risk
2) Primary myelofibrosis.
3) Post-polycythemia vera myelofibrosis.
4) Post-essential thrombocythemia myelofibrosis.
 
Packaging & Shipping
By Express By Air By Sea
Suitable for under 50kg Suitable for more than 50kg Suitable for more than 500kg
Fast: 3-7 days Fast: 3-7 days Slow: 3-10 days
High cost Medium cost Low cost
Door to door service Port to port service Port to port service
Safe Delivery 99% Purity CAS 941678-49-5 Ruxolitinib Raw Powder Ruxolitinib PhosphateSafe Delivery 99% Purity CAS 941678-49-5 Ruxolitinib Raw Powder Ruxolitinib PhosphateSafe Delivery 99% Purity CAS 941678-49-5 Ruxolitinib Raw Powder Ruxolitinib Phosphate

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier